Journal of Medical Ultrasound

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 27  |  Issue : 2  |  Page : 81--85

Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions


Yi-Hong Chou1, Ja-Der Liang2, Shen-Yung Wang3, Shih-Jer Hsu4, Jui-Ting Hu5, Sien-Sing Yang5, Hsin-Kai Wang6, Tien-Ying Lee8, Chui-Mei Tiu8 
1 Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu; Department of Radiology, Taipei Veterans General Hospital and School of Medicine, National Yang Ming University, Taipei; Department of Radiology, Yee Zen General Hospital, Taoyuan, Taiwan
2 Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
3 Department of Medicine, Division of Gastroenterology, MacKay Memorial Hospital, Tamshui Branch, Taipei, Taiwan
4 Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan
5 Liver Center, Cathay General Hospital and School of Medicine, Fu-Jen Catholic University College of Medicine, Taipei, Taiwan
6 Department of Radiology, Taipei Veterans General Hospital and School of Medicine, National Yang Ming University, Taipei, Taiwan

Correspondence Address:
Prof. Yi-Hong Chou
No. 201, Section 2, Shipai Road, Beitou District, Taipei City 11217
Taiwan

Background: The purpose of this study was to report the safety of perfluorobutane (Sonazoid) as a vascular-phase imaging agent in characterizing focal liver lesions (FLLs). Materials and Methods: From May 2014 to April 2015, a total of 54 individuals who received Sonazoid contrast-enhanced ultrasound (CEUS) were enrolled at 5 hospitals of 4 medical centers. All individuals were included in safety evaluation. A prospective study to evaluate the adverse effect (AE) incidences after intravenous administration of Sonazoid. Results: Sonazoid was well tolerated. Treatment-emergent adverse events (TEAEs) representing AE were recorded for 13 (24.1%) patients. The most common AE was abdominal pain (9.3%), followed by heart rate irregularity (5.6%). The majority of these patients (69.2%) experienced TEAEs that were mild in intensity. Sonazoid causes no significant AEs after intravenous injection. The only noteworthy AEs are related to tolerable myalgia (3.7%), abdominal pain (1.9%), and headache (1.9%). None of the 54 patients showed serious adverse effects. Conclusion: Sonazoid shows good safety and tolerance of intravenous use during CEUS of the liver for evaluation of FLLs.


How to cite this article:
Chou YH, Liang JD, Wang SY, Hsu SJ, Hu JT, Yang SS, Wang HK, Lee TY, Tiu CM. Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions.J Med Ultrasound 2019;27:81-85


How to cite this URL:
Chou YH, Liang JD, Wang SY, Hsu SJ, Hu JT, Yang SS, Wang HK, Lee TY, Tiu CM. Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions. J Med Ultrasound [serial online] 2019 [cited 2021 Mar 6 ];27:81-85
Available from: http://www.jmuonline.org/article.asp?issn=0929-6441;year=2019;volume=27;issue=2;spage=81;epage=85;aulast=Chou;type=0